Pre-made Remtolumab benchmark antibody ( Bispecific Dual Variable Domain IG, anti-IL17A/IL17;TNFA/TNF therapeutic antibody, Anti-CTLA-8/CTLA8;DIF/TNF-alpha/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Remtolumab benchmark antibody (Bispecific Dual Variable Domain IG, anti-IL17A/IL17;TNFA/TNF therapeutic antibody, Anti-CTLA-8/CTLA8;DIF/TNF-alpha/TNFSF2/TNLG1F Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Remtolumab (ABT 122) is a dual-variable domain immunoglobulin, targeting tumour necrosis factor (TNF) and interleukin-17 (IL-17), that was being developed by AbbVie, for the treatment of rheumatoid arthritis and psoriatic arthritis.
| Products Name (INN Index) | Pre-Made Remtolumab biosimilar, Bispecific Dual Variable Domain IG: Anti-IL17A/IL17;TNFA/TNF therapeutic antibody |
|---|---|
| INN Name | Remtolumab |
| Target | IL17A,TNFA |
| Format | Bispecific Dual Variable Domain IG |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4nyl:EF:AB:HL:CD/6cr1:HL;None |
| 99% SI Structure | 3wd5:HL;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Abbott Laboratories,AbbVie |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Psoriatic arthritis,Rheumatoid arthritis |
| Development Tech | Dual Variable Domain Immunoglobulin Technology |
| Previous Name | NA |
| Gm Offical Target Name | IL17A,TNFA |
| Package |
